About
Dr. Geng Liu is a Researcher in the Department of Oncology at the University of Oxford, working under Prof. Nick La Thangue. His research focuses on post-translational modifications (acetylation, methylation, ubiquitination) of key transcription factors like E2F1 and p53 in regulating cell cycle and apoptosis in cancer. He also investigates molecular mechanisms of HDAC and PRMT inhibitors as cancer therapies.
Dr. Liu holds a PhD in cancer biology from the University of Dundee. His work bridges basic molecular mechanisms with translational applications, particularly in immunomodulatory and epigenetic therapies.
His research interests include:
- Epigenetic regulation via histone modifications
- HDAC inhibitor mechanisms in cancer immunotherapy
- Ubiquitin-proteasome system in cancer progression
Recent publications highlight his exploration of immune modulation by HDAC inhibitors and the role of non-coding RNA-derived peptides in anti-tumour responses. His work also delves into genomic profiling of proteasome inhibitors' effects and NEDDylation pathways.
No scientific awards or grants are explicitly mentioned in the provided information.
Find Geng Liu elsewhere
Related Searches
You Might Also Like
- NNicholas La ThangueUniversity of Oxford · Professor
Ted LakowskiUniversity of Manitoba · Professor
Tao LiuUniversity of New South Wales · Associate Professor
Hui ZhangUniversity of Nevada, Las Vegas · Professor- GGerald BroschMedical University of Innsbruck · Associate Professor
Sean TavernaUniversity of Arkansas for Medical Sciences · Professor